B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies

REFERENCES

• LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008;112:1570–1580.
   PubMed Web of Science ®Google Scholar
• Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008;224:201–214.
   PubMed Web of Science ®Google Scholar
• Maseda D, Smith SH, DiLillo DJ, Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J Immunol 2012;188:1036–1048.
   PubMedGoogle Scholar
• DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010;1183:38–57.
   PubMed Web of Science ®Google Scholar
• Luther SA, Bidgol A, Hargreaves DC, Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002;169:424–433.
   PubMed Web of Science ®Google Scholar
• Luther SA, Lopez T, Bai W, BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000;12:471–481.
   PubMed Web of Science ®Google Scholar
• McCarthy DD, Summers-Deluca L, Vu F, The lymphotoxin pathway: beyond lymph node development. Immunol Res 2006;35:41–54.
   PubMedGoogle Scholar
• Oliveira HC, Popi AF, Bachi AL, B-1 cells modulate the kinetics of wound-healing process in mice. Immunobiology 2010;215:215–222.
   Google Scholar
• Hippen BE, DeMattos A, Cook WJ, Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005;5:2248–2252.
   PubMed Web of Science ®Google Scholar
• Lehnhardt A, Mengel M, Pape L, Ehrich JH, Offner G, Strehlau J. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. Am J Transplant 2006;6:847–851.
   Google Scholar
• DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010;184:4006–4016.
   PubMed Web of Science ®Google Scholar
• Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005;17:230–236.
   PubMedGoogle Scholar
• Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol 2005;5:880–892.
   PubMed Web of Science ®Google Scholar
• Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 2009;9:845–857.
   PubMed Web of Science ®Google Scholar
• Mattsson PT, Lappalainen I, Backesjo CM, Six X-linked agammaglobulinemia-causing missense mutations in the Src homology 2 domain of Bruton's tyrosine kinase: phosphotyrosine-binding and circular dichroism analysis. J Immunol. 2000;164:4170–4177.
   Google Scholar
• Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). Front Biosci: a journal and virtual library 2000;5:D917–928.
   Google Scholar
• Murakami M, Honjo T. Transgenic mouse models for B-cell dominant autoimmune diseases. Curr Opin Immunol 1997;9:846–850.
   PubMed Web of Science ®Google Scholar
• Fields ML, Erikson J. The regulation of lupus-associated autoantibodies: immunoglobulin transgenic models. Curr Opin Immunol 2003;15:709–717.
   PubMed Web of Science ®Google Scholar
• Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006;24:467–496.
   PubMed Web of Science ®Google Scholar
• Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008;28:18–28.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Matsushita T, B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008;223:284–299.
   PubMed Web of Science ®Google Scholar
• Basten A, Silveira PA. B-cell tolerance: mechanisms and implications. Curr Opin Immunol 2010;22:566–574.
   PubMed Web of Science ®Google Scholar
• Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008;20:632–638.
   PubMed Web of Science ®Google Scholar
• Tighe H, Warnatz K, Brinson D, Peripheral deletion of rheumatoid factor B cells after abortive activation by IgG. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:646–651.
   PubMed Web of Science ®Google Scholar
• Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM: monthly journal of the Association of Physicians 2010;103:139–146.
   PubMed Web of Science ®Google Scholar
• Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002;2:580–592.
   PubMed Web of Science ®Google Scholar
• Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764–766.
   PubMed Web of Science ®Google Scholar
• Herberman RB, Reynolds CW, Ortaldo JR. Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol 1986;4:651–680.
   PubMed Web of Science ®Google Scholar
• Li Y, Li H, Weigert M. Autoreactive B cells in the marginal zone that express dual receptors. J Exp Med 2002;195:181–188.
   PubMed Web of Science ®Google Scholar
• Viau M, Zouali M. B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol (Orlando, Fla) 2005;114:17–26.
   PubMed Web of Science ®Google Scholar
• Pao LI, Lam KP, Henderson JM, B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 2007;27: 35–48.
   PubMed Web of Science ®Google Scholar
• Serreze DV, Chapman HD, Varnum DS, B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. J Exp Med 1996;184:2049–2053.
   PubMed Web of Science ®Google Scholar
• Wong FS, Wen L, Tang M, Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 2004;53:2581–2587.
   PubMed Web of Science ®Google Scholar
• Tian J, Zekzer D, Lu Y, B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J Immunol 2006;176:2654–2661.
   PubMed Web of Science ®Google Scholar
• Falcone M, Lee J, Patstone G, B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 1998;161:1163–1168.
   PubMed Web of Science ®Google Scholar
• Marino E, Grey ST. A new role for an old player: do B cells unleash the self-reactive CD8+ T cell storm necessary for the development of type 1 diabetes? J Autoimmun 2008;31:301–305.
   PubMed Web of Science ®Google Scholar
• Noorchashm H, Lieu YK, Noorchashm N, I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J Immunol 1999;163:743–750.
   PubMed Web of Science ®Google Scholar
• Katz JD, Wang B, Haskins K, Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993;74:1089–1100.
   PubMed Web of Science ®Google Scholar
• Brodie GM, Wallberg M, Santamaria P, B-cells promote intra-islet CD8+ cytotoxic T-cell survival to enhance type 1 diabetes. Diabetes 2008;57:909–917.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev 2008;8:76–82.
   PubMed Web of Science ®Google Scholar
• Lagana B, Vinciguerra M, D'Amelio R. Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept. Clin Drug Investig 2009;29:185–202.
   PubMed Web of Science ®Google Scholar
• Takemura S, Braun A, Crowson C, Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072–1080.
   PubMed Web of Science ®Google Scholar
• Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 2007;7:137–142.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res 2000;2:126–131.
   PubMedGoogle Scholar
• Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. Handbook Exp Pharmacol 2008;181:101–129.
   PubMedGoogle Scholar
• Woodrick R, Ruderman EM. Anti-interleukin-6 therapy in rheumatoid arthritis. Bulletin of the NYU Hosp Joint Dis 2010;68:211–217.
   Google Scholar
• Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 2011;164:1079–1106.
   PubMed Web of Science ®Google Scholar
• t Hart BA, Gran B, Weissert R. EAE: imperfect but useful models of multiple sclerosis. Trends Mol Med 2011;17:119–125.
   Google Scholar
• Yanaba K, Yoshizaki A, Asano Y, IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol 2011;178:735–743.
   PubMedGoogle Scholar
• Davis RE, Ngo VN, Lenz G, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88–92.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563–574.
   PubMed Web of Science ®Google Scholar
• Cecconi D, Zamo A, Bianchi E, Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 2008;8:4495–4506.
   PubMed Web of Science ®Google Scholar
• Pighi C, Gu TL, Dalai I, Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol 2011;34:141–153.
   PubMedGoogle Scholar
• Rinaldi A, Kwee I, Taborelli M, Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132:303–316.
   PubMed Web of Science ®Google Scholar
• Martinez N, Camacho FI, Algara P, The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003;63:8226–8232.
   PubMed Web of Science ®Google Scholar
• Rizzatti EG, Falcao RP, Panepucci RA, Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005;130:516–526.
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Carter RH, Soltoff SP, Fearon DT. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 1993;260:986–989.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Fujimoto Y, Poe JC, CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000;13:47–57.
   PubMed Web of Science ®Google Scholar
• Okada T, Maeda A, Iwamatsu A, BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 2000;13:817–827.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Takeda K, Gotoh K, Essential immunoregulatory role for BCAP in B cell development and function. J Exp Med 2002;195:535–545.
   PubMedGoogle Scholar
• Aiba Y, Kameyama M, Yamazaki T, Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 2008;111:1497–1503.
   PubMed Web of Science ®Google Scholar
• Pierce SK, Liu W. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol 2010;10:767–777.
   PubMed Web of Science ®Google Scholar
• Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006;6:283–294.
   PubMed Web of Science ®Google Scholar
• Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004;117:787–800.
   PubMed Web of Science ®Google Scholar
• Duhren-von Minden M, Ubelhart R, Schneider D, Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012;489:309–312.
   PubMed Web of Science ®Google Scholar
• Agathangelidis A, Darzentas N, Hadzidimitriou A, Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012;119:4467–4475.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329–341.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Leevers SJ, Ahmadi K, Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535–602.
   PubMed Web of Science ®Google Scholar
• Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006;34:647–662.
   PubMed Web of Science ®Google Scholar
• Franke TF, Yang SI, Chan TO, The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727–736.
   PubMed Web of Science ®Google Scholar
• Datta K, Bellacosa A, Chan TO, Tsichlis PN. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem 1996;271:30835–30839.
   PubMed Web of Science ®Google Scholar
• Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657–664.
   PubMed Web of Science ®Google Scholar
• Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells. J Biol Chem 1999;274:10983–10989.
   PubMed Web of Science ®Google Scholar
• Bilancio A, Okkenhaug K, Camps M, Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006;107:642–650.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031–1034.
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196:753–763.
   PubMed Web of Science ®Google Scholar
• Jou ST, Carpino N, Takahashi Y, Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22:8580–8591.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Irie-Sasaki J, Jones RG, Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000;287:1040–1046.
   PubMed Web of Science ®Google Scholar
• Ramadani F, Bolland DJ, Garcon F, The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signaling 2010;3:ra60.
   PubMed Web of Science ®Google Scholar
• Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 2003;170:2647–2654.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Durand CA, Hartvigsen K, Fogelstrand L, Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 2009;183:5673–5684.
   PubMed Web of Science ®Google Scholar
• Dil N, Marshall AJ. Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation. Mol Immunol 2009;46:1970–1978.
   PubMed Web of Science ®Google Scholar
• Kahl B, Byrd JC, Flinn IW, Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, In patients with relapsed or refractory non-hodgkin lymphoma. Blood 2010;116:741–741.
   Web of Science ®Google Scholar
• Durand CA, Richer MJ, Brenker K, Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity 2013;46:62–73.
   PubMed Web of Science ®Google Scholar
• Haylock-Jacobs S, Comerford I, Bunting M, PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J Autoimmun 2011;36:278–287.
   PubMed Web of Science ®Google Scholar
• Maxwell MJ, Tsantikos E, Kong AM, Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease. J Autoimmun 2012;38:381–391.
   PubMed Web of Science ®Google Scholar
• Fung-Leung WP. Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function. Cell Signal 2011;23:603–608.
   PubMed Web of Science ®Google Scholar
• Puri KD, Doggett TA, Douangpanya J, Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 2004;103:3448–3456.
   PubMed Web of Science ®Google Scholar
• Ali K, Bilancio A, Thomas M, Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 2004;431:1007–1011.
   PubMed Web of Science ®Google Scholar
• Ali K, Camps M, Pearce WP, Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 2008; 180:2538–2544.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Patton DT, Bilancio A, The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol 2006;177:5122–5128.
   PubMed Web of Science ®Google Scholar
• Soond DR, Bjorgo E, Moltu K, PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 2010;115:2203–2213.
   PubMed Web of Science ®Google Scholar
• Park SJ, Lee KS, Kim SR, Phosphoinositide 3-kinase delta inhibitor suppresses interleukin-17 expression in a murine asthma model. Eur Respir J 2010;36:1448–1459.
   PubMed Web of Science ®Google Scholar
• Crome SQ, Wang AY, Levings MK. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 2010;159:109–119.
   PubMed Web of Science ®Google Scholar
• Jain R, Tartar DM, Gregg RK, Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 2008;205:207–218.
   PubMed Web of Science ®Google Scholar
• Emamaullee JA, Davis J, Merani S, Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009;58:1302–1311.
   PubMed Web of Science ®Google Scholar
• Sinclair LV, Finlay D, Feijoo C, Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 2008;9:513–521.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Horwitz SM, Patel M, Clinical Safety and activity in a phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta,gamma, in patients with advanced hematologic malignancies. Blood 2012;120: Meeting Abstract: 3663.
   Google Scholar
• Porter JR, Ali J, DiNitto JP, The potent phosphoinositide-3-kinase-(delta,gamma) inhibitor IPI-145 is active in preclinical models of arthritis and well tolerated in healthy adult subjects. Arthritis Rheum 2012;64:S147–S147.
   Google Scholar
• Herman SE, Gordon AL, Wagner AJ, Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078–2088.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Furman M, Winer ES. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Inv Drug 2012;21:15–22.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010;116:1460–1468.
   PubMed Web of Science ®Google Scholar
• Meadws SA, Kashishian A, Johnson D, CAL-101 (GS-1101), a specific inhibitor of phosphatidylinositol-3-kinase-delta (PI3K delta), disrupts signals from the microenvironment, induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of rapamycin (mTOR), in mantle cell lymphoma (MCL). Blood 2011;118:1593–1593.
   Google Scholar
• Iyengar S, Clear AJ, Owen A, PI3K Inhibition with GDC-0941 Has greater efficacy compared to p110 delta-selective inhibition with CAL-101 in mantle cell lymphoma and may be particularly advantageous in multiply relapsed patients. Blood 2011;118:719–719.
   Google Scholar
• Meadows SA, Kashishian A, Johnson D, CAL-101, a potent selective inhibitor of the p110 delta isoform of phosphatidylinositol 3-kinase, attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of hodgkin, lymphoma. Blood 2010;116:1601–1601.
   Google Scholar
• Niedermeier M, Hennessy BT, Knight ZA, Isoform-selective phosphoinositide 3’-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009;113:5549–5557.
   PubMed Web of Science ®Google Scholar
• Longo PG, Laurenti L, Gobessi S, The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846–855.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SEM, CAL-101, a p110 delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Herko A, Mavis C, Czuczman MS, Hernandez F. AMG 319, a novel inhibitor of phosphoinositide-3 kinase delta (PI3Kd), demonstrates activity in lymphoma pre-clinical models. Blood 2012;120: Meeting Abstract: 3718.
   Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603–3612.
   PubMed Web of Science ®Google Scholar
• Meadows SA, Vega F, Kashishian A, PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012;119:1897–1900.
   PubMed Web of Science ®Google Scholar
• Sharman Jde Vos S, Leonard JP, A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3K delta) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2011;118:779–780.
   Web of Science ®Google Scholar
• de Vos S, Schreeder MT, Flinn IW, A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3K delta) inhibitor, Cal-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with previously treated, indolent non-hodgkin lymphoma (iNHL). Blood 2011;118:1160–1160.
   Web of Science ®Google Scholar
• Flinn IW, Schreeder MT, Wagner-Johnston N, A phase 1 study of CAL-101, An isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, In combination with rituximab and/or bendamustine in patients with relapsed or refractory B-cell malignancies. Blood 2010;116:1168–1168.
   Google Scholar
• Brown J, Byrd J, Furman R, Clinical activity in a phase 1 study of Cal-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with B-cell malignancies. Haematol-the Hematol J 2010;95:466–466.
   Google Scholar
• Flinn IW, Byrd JC, Furman RR, Evidence of clinical activity in a phase I study of CAL-101, an Oral P110 delta isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-Cell malignancies. Blood 2009;114:380–380.
   Google Scholar
• Flinn IW, Byrd JC, Furman RR, Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol 2009;27: Meeting Abstract: 3543.
   Google Scholar
• Flinn W, Byrd J, Furman R, Preliminary evidence of clinical activity in a phase 1 study of cal-101, a potent selective inhibitor of the P110delta isoform of phosphatidylinositol 3-kinase, in patient with B-cell malignancies. Haematologica-the Hematol J 2009;94:303–303.
   Google Scholar
• Furman RR, Byrd JC, Brown JR, CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects In patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;116:31–31.
   Web of Science ®Google Scholar
• Kahl B, Byrd J, Flinn I, Significant clinical activity of cal-101, an isoform-selective inhibitor of phosphatidylinositol 3 kinase P110d, in patients with relapsed or refractory indolent and mantle cell lymphoma. Ann Oncol 2011;22:199–199.
   Google Scholar
• Leonard J, Schreeder M, Coutre S, A phase 1 study of cal-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in combination with anti-Cd20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. Ann Oncol 2011;22:137–137.
   Web of Science ®Google Scholar
• Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 2004;173:2236–2240.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Kobayashi T, Kondo J, Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 1991;266:15790–15796.
   PubMed Web of Science ®Google Scholar
• Arias-Palomo E, Recuero-Checa MA, Bustelo XR, Llorca O. 3D structure of Syk kinase determined by single-particle electron microscopy. Biochim Biophys Acta 2007;1774:1493–1499.
   Google Scholar
• Gradler U, Schwarz D, Dresing V, Structural and biophysical characterization of the Syk activation switch. J Mol Biol 2013;425:309–333.
   PubMedGoogle Scholar
• Tsang E, Giannetti AM, Shaw D, Molecular mechanism of the Syk activation switch. J Biol Chem 2008;283:32650–32659.
   PubMedGoogle Scholar
• Kurosaki T, Kurosaki M. Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function. J Biol Chem 1997;272:15595–15598.
   PubMed Web of Science ®Google Scholar
• Rolli V, Gallwitz M, Wossning T, Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol Cell 2002;10:1057–1069.
   PubMed Web of Science ®Google Scholar
• de Castro RO, Zhang J, Jamur MC, Tyrosines in the carboxyl terminus regulate Syk kinase activity and function. J Biol Chem 2010;285:26674–26684.
   PubMedGoogle Scholar
• Kurosaki T, Johnson SA, Pao L, Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med 1995;182:1815–1823.
   PubMed Web of Science ®Google Scholar
• Furlong MT, Mahrenholz AM, Kim KH, Identification of the major sites of autophosphorylation of the murine protein-tyrosine kinase Syk. Biochim Biophys Acta 1997;1355:177–190.
   PubMed Web of Science ®Google Scholar
• Keshvara LM, Isaacson C, Harrison ML, Geahlen RL. Syk activation and dissociation from the B-cell antigen receptor is mediated by phosphorylation of tyrosine 130. J Biol Chem 1997;272:10377–10381.
   PubMedGoogle Scholar
• Zhang Y, Oh H, Burton RA, Tyr130 phosphorylation triggers Syk release from antigen receptor by long-distance conformational uncoupling. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:11760–11765.
   Google Scholar
• Kulathu Y, Hobeika E, Turchinovich G, Reth M. The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development. The EMBO J 2008;27:1333–1344.
   PubMed Web of Science ®Google Scholar
• DeFranco AL. Transmembrane signaling by antigen receptors of B and T lymphocytes. Curr Opin Cell Biol 1995;7:163–175.
   PubMedGoogle Scholar
• DeFranco AL. The complexity of signaling pathways activated by the BCR. Curr Opin Immunol 1997;9:296–308.
   PubMedGoogle Scholar
• Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem 2001;130:177–186.
   PubMed Web of Science ®Google Scholar
• Vendel AC, Calemine-Fenaux J, Izrael-Tomasevic A, B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol 2009;182:1509–1517.
   Google Scholar
• Cheng AM, Rowley B, Pao W, Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995;378:303–306.
   PubMed Web of Science ®Google Scholar
• Turner M, Mee PJ, Costello PS, Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995;378:298–302.
   PubMed Web of Science ®Google Scholar
• Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Inv Drug 2004;13:743–762.
   PubMed Web of Science ®Google Scholar
• Tan SL, Liao C, Lucas MC, Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol Ther 2013;138:294–309.
   PubMed Web of Science ®Google Scholar
• Mallick-Wood CA, Pao W, Cheng AM, Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:9704–9709.
   PubMedGoogle Scholar
• Gong Q, White L, Johnson R, Restoration of thymocyte development and function in zap-70-/- mice by the Syk protein tyrosine kinase. Immunity 1997;7:369–377.
   PubMedGoogle Scholar
• Geahlen RL, Burg DL. The role of Syk in cell signaling. Adv Exp Med Biol 1994;365:103–109.
   Google Scholar
• Law CL, Sidorenko SP, Chandran KA, Molecular cloning of human Syk. A B cell protein-tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex. J Biol Chem 1994;269:12310–12319.
   PubMedGoogle Scholar
• Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010;10:387–402.
   PubMed Web of Science ®Google Scholar
• Turner M, Schweighoffer E, Colucci F, Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 2000;21:148–154.
   PubMedGoogle Scholar
• Abtahian F, Guerriero A, Sebzda E, Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 2003;299:247–251.
   PubMed Web of Science ®Google Scholar
• Braselmann S, Taylor V, Zhao H, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006;319:998–1008.
   PubMed Web of Science ®Google Scholar
• Coffey G, DeGuzman F, Inagaki M, Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012;340:350–359.
   PubMed Web of Science ®Google Scholar
• Le Roux D, Lankar D, Yuseff MI, Syk-dependent actin dynamics regulate endocytic trafficking and processing of antigens internalized through the B-cell receptor. Mol Biol Cell 2007;18:3451–3462.
   Web of Science ®Google Scholar
• Katkere B, Rosa S, Drake JR. The Syk-binding ubiquitin ligase c-Cbl mediates signaling-dependent B cell receptor ubiquitination and B cell receptor-mediated antigen processing and presentation. J Biol Chem 2012;287:16636–16644.
   Google Scholar
• Burger JA, Quiroga MP, Hartmann E, High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050–3058.
   PubMed Web of Science ®Google Scholar
• Quiroga MP, Balakrishnan K, Kurtova AV, B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029–1037.
   PubMed Web of Science ®Google Scholar
• Buchner M, Baer C, Prinz G, Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010;115: 4497–4506.
   PubMed Web of Science ®Google Scholar
• Fruchon S, Kheirallah S, Al Saati T, Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia 2012;26:795–805.
   PubMedGoogle Scholar
• Chen L, Monti S, Juszczynski P, SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230–2237.
   PubMed Web of Science ®Google Scholar
• Spurgeon SE, Coffey G, Fletcher LB, The selective SYK inhibitor P505–15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther 2013;344:378–387.
   PubMed Web of Science ®Google Scholar
• Cheng S, Coffey G, Zhang XH, SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011;118:6342–6352.
   PubMed Web of Science ®Google Scholar
• Liubchenko GA, Appleberry HC, Striebich CC, Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun 2013;40: 111–121.
   PubMed Web of Science ®Google Scholar
• Pine PR, Chang B, Schoettler N, Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol (Orlando, Fla.) 2007;124:244–257.
   PubMed Web of Science ®Google Scholar
• Tsokos GC, Liossis SN. Immune cell signaling defects in lupus: activation, anergy and death. Immunol Today 1999;20:119–124.
   PubMedGoogle Scholar
• Shahaf G, Gross AJ, Sternberg-Simon M, Lyn deficiency affects B-cell maturation as well as survival. Eur J Immunol 2012;42:511–521.
   Google Scholar
• Anolik JH, Barnard J, Cappione A, Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580–3590.
   PubMed Web of Science ®Google Scholar
• Bahjat FR, Pine PR, Reitsma A, An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008;58:1433–1444.
   PubMed Web of Science ®Google Scholar
• Deng GM, Liu L, Bahjat FR, Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010;62:2086–2092.
   PubMed Web of Science ®Google Scholar
• Smith J, McDaid JP, Bhangal G, A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol: JASN. 2010;21:231–236.
   PubMed Web of Science ®Google Scholar
• Colonna L, Catalano G, Chew C, Therapeutic targeting of Syk in autoimmune diabetes. J Immunol 2010;185:1532–1543.
   PubMed Web of Science ®Google Scholar
• Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113:3154–3160.
   PubMed Web of Science ®Google Scholar
• Iwata S, Yamaoka K, Niiro H, Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. J Allergy Clin Immunol 2012;129:1594–1601 e1592.
   Google Scholar
• Carreno C, Domenech A, Prats N, Miralpeix M, Ramis I. Characterization of a model of tracheal plasma extravasation in passively sensitized rats using anti-allergic and anti-inflammatory drugs by oral and intratracheal route. Pulm Pharmacol Ther 2012;25:87–93.
   Google Scholar
• Sanderson MP, Gelling SJ, Rippmann JF, Schnapp A. Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells. Cell Immunol 2010;262:28–34.
   Google Scholar
• Matsubara S, Koya T, Takeda K, Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2006;34:426–433.
   Web of Science ®Google Scholar
• Matsubara S, Li G, Takeda K, Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006;173:56–63.
   PubMed Web of Science ®Google Scholar
• Kuno Y, Abe A, Emi N, Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood. 2001;97:1050–1055.
   PubMed Web of Science ®Google Scholar
• Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2006;20:313–318.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003;21:841–894.
   PubMed Web of Science ®Google Scholar
• Kipps TJ. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res 2007;20:415–424.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103:4389–4395.
   PubMed Web of Science ®Google Scholar
• Tauzin S, Ding H, Burdevet D, Borisch B, Hoessli DC. Membrane-associated signaling in human B-lymphoma lines. Exp Cell Res 2011;317:151–162.
   PubMed Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG, Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009;23:686–697.
   PubMed Web of Science ®Google Scholar
• Suljagic M, Longo PG, Bennardo S, The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010;116:4894–4905.
   PubMed Web of Science ®Google Scholar
• Young RM, Hardy IR, Clarke RL, Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009;113:2508–2516.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kavanaugh A, Weinblatt ME, An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63:337–345.
   PubMed Web of Science ®Google Scholar
• Scott DL. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. Drugs 2011;71:1121–1132.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309–3318.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303–1312.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005;115:791–796.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578–2585.
   PubMed Web of Science ®Google Scholar
• Baluom M, Samara E, Grossbard EB, Lau DT. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol 2011;51:1310–1318.
   PubMed Web of Science ®Google Scholar
• Tsukada S, Saffran DC, Rawlings DJ, Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279–290.
   PubMed Web of Science ®Google Scholar
• Mohamed AJ, Nore BF, Christensson B, Smith CI. Signalling of Bruton's tyrosine kinase, Btk. Scand J Immunol 1999;49:113–118.
   Google Scholar
• Baraldi E, Djinovic C.arugo K Hyvonen M, Structure of the PH domain from Bruton's tyrosine kinase in complex with inositol 1,3,4,5-tetrakisphosphate. Structure 1999;7:449–460.
   PubMed Web of Science ®Google Scholar
• Hyvonen M, Saraste M. Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. The EMBO J 1997;16:3396–3404.
   PubMed Web of Science ®Google Scholar
• Murayama K, Kato-Murayama M, Mishima C, Crystal structure of the Bruton's tyrosine kinase PH domain with phosphatidylinositol. Biochem Biophys Res Commun 2008;377:23–28.
   Google Scholar
• Li T, Tsukada S, Satterthwaite A, Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity 1995;2:451–460.
   PubMed Web of Science ®Google Scholar
• Wahl MI, Fluckiger AC, Kato RM, Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:11526–11533.
   PubMed Web of Science ®Google Scholar
• Mao C, Zhou M, Uckun FM. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem 2001;276:41435–41443.
   PubMed Web of Science ®Google Scholar
• Park H, Wahl MI, Afar DE, Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 1996;4:515–525.
   PubMed Web of Science ®Google Scholar
• Mohamed AJ, Yu L, Backesjo CM, Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009;228:58–73.
   PubMed Web of Science ®Google Scholar
• Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 2000;191:1735–1744.
   PubMed Web of Science ®Google Scholar
• Yao L, Suzuki H, Ozawa K, Interactions between protein kinase C and pleckstrin homology domains. Inhibition by phosphatidylinositol 4,5-bisphosphate and phorbol 12-myristate 13-acetate. J Biol Chem 1997;272:13033–13039.
   Google Scholar
• Venkataraman C, Chen XC, Na S, Lee L, Neote K, Tan SL. Selective role of PKCbeta enzymatic function in regulating cell survival mediated by B cell antigen receptor cross-linking. Immunol Lett 2006;105:83–89.
   PubMed Web of Science ®Google Scholar
• Yu L, Mohamed AJ, Vargas L, Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1. J Biol Chem 2006;281:18201–18207.
   PubMedGoogle Scholar
• Ochs HD, Smith CI. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine 1996;75:287–299.
   PubMed Web of Science ®Google Scholar
• Rawlings DJ, Saffran DC, Tsukada S, Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993;261:358–361.
   PubMed Web of Science ®Google Scholar
• Satoh M, Mizutani A, Behney KM, X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus. Int Immunol 2003;15:1117–1124.
   PubMed Web of Science ®Google Scholar
• Currie KS. Targeting B-cells in Inflammatory Disease. Annu Rep Med Chem 2010;45:175–190.
   Google Scholar
• Di Paolo JA, Huang T, Balazs M, Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 2011;7:41–50.
   PubMed Web of Science ®Google Scholar
• Liu L, Di Paolo J, Barbosa J, Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/ pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther 2011;338:154–163.
   PubMed Web of Science ®Google Scholar
• Xu D, Kim Y, Postelnek J, RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther 2012;341:90–103.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Human B cell tolerance and its failure in rheumatoid arthritis. Ann N Y Acad Sci. 2005;1062:116–126.
   PubMed Web of Science ®Google Scholar
• Chang BY, Huang MM, Francesco M, The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011;13:R115.
   PubMed Web of Science ®Google Scholar
• Jumaa H, Hendriks RW, Reth M. B cell signaling and tumorigenesis. Annu Rev Immunol 2005;23:415–445.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287–6296.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012;120:4684–4691.
   PubMed Web of Science ®Google Scholar
• Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malignancy Rep 2013;8:1–6.
   PubMed Web of Science ®Google Scholar
• Brown JR, Sharman JP, Harb WA, Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). J Clin Oncol 2012;30.
   Google Scholar
• Jaglowski SM, Jones JA, Flynn JM, A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 2012;30.
   Google Scholar